JP6180114B2 - Ｔ細胞受容体 - Google Patents

Ｔ細胞受容体 Download PDF

Info

Publication number
JP6180114B2
JP6180114B2 JP2012531494A JP2012531494A JP6180114B2 JP 6180114 B2 JP6180114 B2 JP 6180114B2 JP 2012531494 A JP2012531494 A JP 2012531494A JP 2012531494 A JP2012531494 A JP 2012531494A JP 6180114 B2 JP6180114 B2 JP 6180114B2
Authority
JP
Japan
Prior art keywords
tcr
chain
cell
seq
ebv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012531494A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505734A5 (enExample
JP2013505734A (ja
Inventor
ハンス シュタウス，
ハンス シュタウス，
シャオ−アン シュー，
シャオ−アン シュー，
マックス トップ，
マックス トップ，
Original Assignee
ユーシーエル ビジネス ピーエルシー
ユーシーエル ビジネス ピーエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーシーエル ビジネス ピーエルシー, ユーシーエル ビジネス ピーエルシー filed Critical ユーシーエル ビジネス ピーエルシー
Publication of JP2013505734A publication Critical patent/JP2013505734A/ja
Publication of JP2013505734A5 publication Critical patent/JP2013505734A5/ja
Application granted granted Critical
Publication of JP6180114B2 publication Critical patent/JP6180114B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/05—Epstein-Barr virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2012531494A 2009-09-29 2010-09-28 Ｔ細胞受容体 Expired - Fee Related JP6180114B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0917090.3A GB0917090D0 (en) 2009-09-29 2009-09-29 T-cell receptor
GB0917090.3 2009-09-29
PCT/GB2010/001821 WO2011039508A2 (en) 2009-09-29 2010-09-28 T-cell receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015219230A Division JP2016047064A (ja) 2009-09-29 2015-11-09 Ｔ細胞受容体

Publications (3)

Publication Number Publication Date
JP2013505734A JP2013505734A (ja) 2013-02-21
JP2013505734A5 JP2013505734A5 (enExample) 2013-08-22
JP6180114B2 true JP6180114B2 (ja) 2017-08-16

Family

ID=41350560

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012531494A Expired - Fee Related JP6180114B2 (ja) 2009-09-29 2010-09-28 Ｔ細胞受容体
JP2015219230A Pending JP2016047064A (ja) 2009-09-29 2015-11-09 Ｔ細胞受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015219230A Pending JP2016047064A (ja) 2009-09-29 2015-11-09 Ｔ細胞受容体

Country Status (10)

Country Link
US (1) US8889141B2 (enExample)
EP (1) EP2483294B1 (enExample)
JP (2) JP6180114B2 (enExample)
KR (1) KR101760277B1 (enExample)
CN (1) CN102695717B (enExample)
AU (1) AU2010302477B2 (enExample)
ES (1) ES2584541T3 (enExample)
GB (1) GB0917090D0 (enExample)
IN (1) IN2012DN02993A (enExample)
WO (1) WO2011039508A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
EP2694640B1 (en) 2011-04-08 2017-10-18 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
RS61455B1 (sr) 2011-10-28 2021-03-31 Regeneron Pharma Genetski modifikovani miševi t ćelijskog receptora
BR112014014591A8 (pt) 2011-12-12 2017-07-04 Baylor College Medicine processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
EP3495483A1 (en) 2012-09-12 2019-06-12 International Institute of Cancer Immunology, Inc. Antigen-specific helper t-cell receptor genes
CN110511960B (zh) * 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
PT3149031T (pt) * 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
WO2015199618A1 (en) * 2014-06-24 2015-12-30 National University Of Singapore Epstein-barr virus lmp2 specific antibody and uses thereof
PL3212225T3 (pl) 2014-10-31 2026-03-30 The Trustees Of The University Of Pennsylvania Sposoby i kompozycje zmodyfikowanych limfocytów t
WO2016095783A1 (zh) * 2014-12-17 2016-06-23 中国科学院广州生物医药与健康研究院 识别eb病毒短肽的t细胞受体
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
MX2017012829A (es) 2015-04-06 2018-02-23 Regeneron Pharma Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
CN104830793A (zh) * 2015-05-05 2015-08-12 杨光华 基于lmp-1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途
IL281396B (en) * 2015-06-09 2022-07-01 Memorial Sloan Kettering Cancer Center T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
KR101794304B1 (ko) 2015-09-01 2017-11-06 가톨릭대학교 산학협력단 Ｅｂｖ 항원 특이 ｔ―세포 수용체 및 이의 용도
US11167024B2 (en) 2015-09-18 2021-11-09 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
GB201520191D0 (en) * 2015-11-16 2015-12-30 Cancer Rec Tech Ltd T-cell receptor and uses thereof
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
CN109963860A (zh) * 2016-09-19 2019-07-02 拜耳作物科学股份公司 吡唑并[1,5-a]吡啶衍生物及其作为农药的用途
CN108218976B (zh) * 2016-12-09 2021-11-05 香雪生命科学技术（广东）有限公司 衍生自lmp1的肿瘤抗原短肽
WO2019031938A2 (ko) 2017-08-10 2019-02-14 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
EP3773633A4 (en) 2018-04-06 2022-01-26 The Regents of The University of California METHODS OF TREATMENT OF GLIOBLASTOMA
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
SG11202101671PA (en) 2018-11-27 2021-03-30 Univ Duke Anti-lmp2 tcr-t cell therapy for the treatment of ebv-associated cancers
WO2020133050A1 (zh) * 2018-12-27 2020-07-02 深圳华大生命科学研究院 Ebv表位高亲和力t细胞受体
EP3786178A1 (en) * 2019-08-30 2021-03-03 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for ebv-derived antigens
WO2021211455A1 (en) * 2020-04-13 2021-10-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against lmp2
WO2021243695A1 (en) * 2020-06-05 2021-12-09 Guangdong Tcrcure Biopharma Technology Co., Ltd. Tcr-t cell therapy targeting epstein-barr virus
EP3940075A1 (en) * 2020-07-17 2022-01-19 Istituto Nazionale Di Genetica Molecolare-INGM Inhibitors of line1 and uses thereof
CN116981357A (zh) 2021-03-31 2023-10-31 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
EP4091627A1 (en) 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
CN113773378B (zh) * 2021-10-14 2023-11-03 深圳大学总医院 T细胞受体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101182531B (zh) * 2007-11-09 2010-06-02 暨南大学 Eb病毒特异性tcr基因相关的重组质粒及构建抗ebv特异性ctl的方法

Also Published As

Publication number Publication date
US20120244132A1 (en) 2012-09-27
EP2483294B1 (en) 2016-07-13
CN102695717B (zh) 2016-08-10
GB0917090D0 (en) 2009-11-11
JP2016047064A (ja) 2016-04-07
IN2012DN02993A (enExample) 2015-07-31
AU2010302477B2 (en) 2017-01-19
US8889141B2 (en) 2014-11-18
KR101760277B1 (ko) 2017-07-21
WO2011039508A3 (en) 2011-06-30
EP2483294A2 (en) 2012-08-08
WO2011039508A2 (en) 2011-04-07
JP2013505734A (ja) 2013-02-21
AU2010302477A1 (en) 2012-04-19
CN102695717A (zh) 2012-09-26
ES2584541T3 (es) 2016-09-28
KR20120074291A (ko) 2012-07-05

Similar Documents

Publication Publication Date Title
JP2016047064A (ja) Ｔ細胞受容体
EP2483303B1 (en) T-cell receptor capable of recognising an antigen from cytomegalovirus
RU2665548C2 (ru) Способ получения клеток, экспрессирующих т-клеточный рецептор
AU2017205637B2 (en) Compositions and libraries comprising recombinant T-cell receptors and methods of using recombinant T-cell receptors
US10538572B2 (en) T cell immunotherapy specific for WT-1
JP2019525898A (ja) ヒト白血球抗原拘束ガンマデルタｔ細胞受容体及びその使用方法
CN102083979A (zh) Hbv表位反应性外源t细胞受体(tcr)及其用途
WO2020089433A2 (en) Tcr and peptides
WO2016095783A1 (zh) 识别eb病毒短肽的t细胞受体
CN110857319A (zh) 一种分离的t细胞受体、其修饰的细胞、编码核酸及其应用
CN110272482A (zh) 识别prame抗原短肽的t细胞受体
US10251936B2 (en) EBV antigen specific T-cell receptor and use thereof
KR20230112654A (ko) Ras 돌연변이 에피토프 펩티드 및 ras 돌연변이체를 인식하는 t 세포 수용체
WO2018077242A1 (zh) 识别sage1抗原短肽的t细胞受体
CN115786268A (zh) 工程化免疫细胞及其用途
WO2025255344A1 (en) Compositions and methods for engineering tregs for treatment of diabetes
WO2023071811A1 (zh) 工程化免疫细胞及其用途
JP2024537353A (ja) 改変された結合タンパク質及びその治療上の使用
CN116103239A (zh) 工程化免疫细胞及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130704

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151221

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160120

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170718

R150 Certificate of patent or registration of utility model

Ref document number: 6180114

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees